Michael Vi
- The US FDA has granted an additional indication for Merck's (NYSE:MRK) Keytruda (pembrolizumab) as a adjuvant therapy for non-small cell lung cancer (NSCLC).
- More specifically, the new indication is for NSCLC patients following resection and platinum-based chemotherapy.
- Keytruda has four other indications just in NSCLC.
- Read why Seeking Alpha contributor Jonathan Weber says that Merck (MRK) is a hold as shares have gotten expensive.